KUMAR AMIT purchased $8K of ANIX
KUMAR AMIT (Chief Executive Officer) purchased 3,000 shares of Anixa Biosciences Inc (ANIX) at $2.75 on 2026-09-10.
Anixa Biosciences Inc
KUMAR AMIT (Chief Executive Officer) purchased 3,000 shares of Anixa Biosciences Inc (ANIX) at $2.75 on 2026-09-10.
Titterton Lewis H jr purchased 10,000 shares of Anixa Biosciences Inc (ANIX) at $2.73 on 2026-09-10.
RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ANIX (Anixa Biosciences Inc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ANIX coverage spans insider activity, technology and financial news.
In the last 30 days, ANIX insiders filed 3 SEC Form 4 transactions — 3 purchases ($49K) and no sales. The most active reporter was KUMAR AMIT, Chief Executive Officer, with 2 filings.
Small insider purchase, unlikely to move price materially.
Minor insider buy may signal confidence but size is negligible.
Positive early-stage data may boost valuation and attract partnership interest.
Small insider purchase signals confidence but limited material impact.
CEO buying can be a sentiment tailwind, but the article’s fair-value overhang and only modest weekly move reduce conviction.
AlphAI scores every news story that mentions ANIX with an AI model for sentiment and relevance, and aggregates insider trades from Anixa Biosciences Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
KUMAR AMIT (Chief Executive Officer) purchased 3,000 shares of Anixa Biosciences Inc (ANIX) at $2.75 on 2026-09-10.
1 min readTitterton Lewis H jr purchased 10,000 shares of Anixa Biosciences Inc (ANIX) at $2.73 on 2026-09-10.
1 min readRedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.
2 min readKUMAR AMIT (Chief Executive Officer) purchased 5,000 shares of Anixa Biosciences Inc (ANIX) at $2.76 on 2026-09-10.
1 min readInvesting.com reported Monday’s SEC Form 4 insider trades for several US-listed firms. Buys included Hanover Bancorp (HNVR) President Kevin O’Connor buying 10,000 shares at $26.88, Protagenic Therapeutics (PTIX) executive chair buying 26,291 shares at $0.1828, and V F Corp (VFC) CEO buying 32,894 shares at ~$14.98. Sales included Snowflake (SNOW) EVP selling 29,986 shares at $300 and Cactus (WHD) leaders selling 86,700 shares each at $57.618.
7 min readKUMAR AMIT (Chief Executive Officer) purchased 5,000 shares of Anixa Biosciences Inc (ANIX) at $3.47 on 2026-07-31.
1 min readKUMAR AMIT (Chief Executive Officer) purchased 5,000 shares of Anixa Biosciences Inc (ANIX) at $3.44 on 2026-07-27.
2 min readKUMAR AMIT (Chief Executive Officer) purchased 3,188 shares of Anixa Biosciences Inc (ANIX) at $3.37 on 2026-07-27.
1 min readKUMAR AMIT (Chief Executive Officer) purchased 3,000 shares of Anixa Biosciences Inc (ANIX) at $3.73 on 2026-07-24.
1 min readKUMAR AMIT (Chief Executive Officer) purchased 5,000 shares of Anixa Biosciences Inc (ANIX) at $3.46 on 2026-07-20.
1 min read